US 11,676,269 B2
Automated pattern recognition and scoring method of histological images
John Brozek, Saint-Amand-les-Eaux (FR); Nathalie Degallaix, Ervillers (FR); Benoit Noel, Gondecourt (FR); and Elton Rexhepaj, Antibes (FR)
Assigned to GENFIT, Loos (FR)
Appl. No. 16/757,752
Filed by GENFIT, Loos (FR)
PCT Filed Oct. 19, 2018, PCT No. PCT/EP2018/078711
§ 371(c)(1), (2) Date Apr. 20, 2020,
PCT Pub. No. WO2019/077108, PCT Pub. Date Apr. 25, 2019.
Claims priority of application No. 17197623 (EP), filed on Oct. 20, 2017; and application No. 18166425 (EP), filed on Apr. 9, 2018.
Prior Publication US 2021/0192722 A1, Jun. 24, 2021
Int. Cl. G06K 9/00 (2022.01); G06T 7/00 (2017.01); G16H 10/40 (2018.01); G16H 30/20 (2018.01); G16H 50/30 (2018.01); G16H 50/70 (2018.01); G16H 50/20 (2018.01); G16H 30/40 (2018.01); G06N 3/04 (2023.01); G06N 3/08 (2023.01)
CPC G06T 7/0012 (2013.01) [G06N 3/04 (2013.01); G06N 3/08 (2013.01); G16H 10/40 (2018.01); G16H 30/20 (2018.01); G16H 30/40 (2018.01); G16H 50/20 (2018.01); G16H 50/30 (2018.01); G16H 50/70 (2018.01); G06T 2207/10056 (2013.01); G06T 2207/20081 (2013.01); G06T 2207/30024 (2013.01); G06T 2207/30056 (2013.01)] 10 Claims
OG exemplary drawing
 
3. A method for diagnosing NASH in a subject, the method comprising:
providing a liver biopsy slide from said subject;
using a deep learning model:
determining a plurality of field of views (FOVs) on a digitized form of the liver biopsy slide; and
selecting a subset of the plurality of FOVs and identifying inflammatory cell patterns within the subset of the plurality of FOVs;
identifying patterns of hepatocyte ballooning (HB) and score hepatocyte ballooning;
determining a hepatocyte lobular inflammation (LI) score for the liver biopsy slide based on the identified inflammatory cell patterns;
wherein the LI score ranges from 0 to 3 and LI=0 corresponds to no inflammation, LI=1 corresponds to mild inflammation, LI=2 corresponds to moderate inflammation, and LI=3 corresponds to severe inflammation; and
wherein HB score ranges from 0 to 2 and HB=0 corresponds to no hepatocyte ballooning, HB=1 corresponds to moderate hepatocyte ballooning, and HB=2 corresponds to severe hepatocyte ballooning and wherein said HB score and said LI score are added to determine an Activity Index (AI), ranking from 0 to 5, wherein the subject is diagnosed as a NASH subject if AI≥2, with HB≥1 and LI≥1.